Clik here to view.
Report: J&J set for EU OK on Synthes buyout | Wall Street Beat
European Union regulators are poised to give the OK to Johnson & Johnson‘s (NYSE:JNJ) $21.3 billion acquisition of Swiss orthopedic giant Synthes, according to Reuters. The anti-trust regulators...
View ArticleClik here to view.
J&J ditches DePuy trauma business ahead of Synthes merger
Updated April 3, 2012, at 1:00 p.m. with comments from Biomet. Biomet Inc. signed a binding offer to pay $280 million in cash for Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopedics‘ global...
View ArticleClik here to view.
MassDevice.com +3 | The top 3 med-tech stories for April 3, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the...
View ArticleClik here to view.
Former Synthes sales rep counter-sues in generic ortho devices battle
Former Synthes Inc. sales rep John Marotta fought back against his erstwhile employer, lodging a counterclaim alleging antitrust violations and claiming that the device giant is using litigation to...
View ArticleClik here to view.
EU clears J&J’s $21B Synthes buyout | Wall Street Beat
Johnson & Johnson‘s (NYSE:JNJ) move to ditch its DePuy trauma business mollified EuroZone anti-trust regulators enough to win their approval for its $21.3 billion buyout of Synthes Inc. The deal,...
View ArticleClik here to view.
MassDevice.com +3 | The top 3 med-tech stories for April 19, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the...
View ArticleClik here to view.
MassDevice.com +7 | The top 7 med-tech stories for the week of April 16, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories...
View ArticleClik here to view.
Baxter dialysis IP battle headed for the Supreme Court? | Legal News
Baxter hemodialysis intellectual property spat may head to the Supreme Court A years-long intellectual property lawsuit between Baxter (NYSE:BAX) and Fresenius (NYSE:FMS) may be headed to the Supreme...
View ArticleClik here to view.
J&J’s DePuy Orthopaedics OKs Biomet bid for trauma business
Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopedics accepted a $280 million cash offer for its global trauma business from Biomet Inc., part of concessions the healthcare conglomerate made...
View ArticleClik here to view.
U.S. approves J&J’s $21B offer for Synthes with caveats, deal may close this...
A long-awaited merger between Johnson & Johnson (NYSE:JNJ) and Synthes Inc. may come to a close this week, after U.S. anti-trust regulators approved the $21.3 billion acquisition. The Federal...
View ArticleClik here to view.
MassDevice.com +3 | The top 3 med-tech stories for June 12, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the...
View ArticleClik here to view.
MassDevice.com +3 | The top 3 med-tech stories for June 13, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the...
View ArticleClik here to view.
J&J: $19.7B Synthes buyout should boost earnings
Johnson & Johnson (NYSE:JNJ) and Synthes Inc. officially sealed the deal today after more than a year of wrangling with government authorities, with J&J announcing a reorganized payment...
View ArticleClik here to view.
MassDevice.com +3 | The top 3 med-tech stories for June 14, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the...
View ArticleClik here to view.
MassDevice.com +7 | The top 7 med-tech stories for the week of June 11, 2012
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories...
View ArticleClik here to view.
Medical device companies: Who spends the most on R&D?
Across the medical device industry, R&D spending in 2011 increased despite a lethargic economy, job cuts and reorganization mandates by a number of big-name companies. Want more data? Download the...
View ArticleClik here to view.
Synthes recalls bone putty over potential to “ignite”
Newly acquired Synthes Inc. recalled certain lots of its Hemostatic Bone Putty over concerns that the product may catch on fire in certain conditions. The product, which is used to stop bone bleeding...
View ArticleClik here to view.
Medical device companies: Who’s hiring?
The economic recovery has been slow going in the U.S. as the housing market and persistently high unemployment have proven particularly stubborn. That’s why we were surprised, after looking at the...
View ArticleClik here to view.
Medical Device Companies: Medtech’s best/worst valued stocks
One way to assess stock values is to compare the stock’s share price with its asset value. The latter is the number of shares outstanding divided into total assets. When the result is compared with...
View ArticleClik here to view.
Medical device earnings: Johnson & Johnson sees declines in several medtech...
Healthcare titan Johnson & Johnson (NYSE:JNJ) scored some hits and misses with Wall Street upon releasing its 1st-quarter 2013 earnings report, touting a 10% overall increase in medical devices...
View Article
